Cincinnati-based CinCor Pharma snagged $50 million in Series A financing, as well as rights to a Roche therapy for treatment-resistant hypertension and primary aldosteronism, a hormonal disorder that can lead to high blood pressure.
Click here to read the complete article.
Story excerpt provided by BioSpace.
Written by Alex Keown.
Originally published May 15, 2019.